EGFR and lung adenocarcinoma: In our study, age (p = 0.372), gender (p = 0.359), smoking habits (p = 0.522), operation (p = 0.586), tumor differentiation (p = 0.19), EGFR mutation status (p = 0.196), location (p = 0.633), CEA level (p = 0.67), LVSI (p = 0.289), VPI (p = 0.348), pathologic stage (p = 0.72), tumor size (p = 0.373) and GGO ratio (p = 0.443) were not statistically significant between the groups with and without EBUS TBNA for recurrent lung adenocarcinoma.